pyrazines has been researched along with Leukemia, Myeloid, Acute in 164 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.83) | 18.7374 |
| 1990's | 2 (1.22) | 18.2507 |
| 2000's | 16 (9.76) | 29.6817 |
| 2010's | 73 (44.51) | 24.3611 |
| 2020's | 70 (42.68) | 2.80 |
| Authors | Studies |
|---|---|
| Cimino, G; Cipollone, E; Ortu La Barbera, E; Ottone, T; Perrone, S; Scerpa, MC; Siniscalchi, R; Viola, F; Voso, MT | 1 |
| Cuglievan, B; Daver, N; DiNardo, C; Kadia, TM; Mahadeo, KM; McCall, D; Nunez, C; Roth, M; Short, NJ; Toepfer, L; Yi, JS | 1 |
| Baker, SD; Buelow, DR; Campbell, MJ; Jeon, JY; Pabla, N; Silvaroli, J; Sparreboom, A; Talebi, Z; Zavorka Thomas, ME | 1 |
| Garnham, A; Pandya, BJ; Qi, CZ; Shah, MV; Yang, H; Zeidan, AM | 1 |
| Thol, F | 1 |
| Atallah, E; Chiba, S; Hasabou, N; Hosono, N; Kim, HJ; Larson, RA; Levis, MJ; Lu, Q; Martinelli, G; Montesinos, P; Neubauer, A; Onozawa, M; Perl, AE; Podoltsev, NA; Récher, C; Schiller, GJ; Sierra, J; Strickland, S; Tiu, R; Wang, ES; Yoon, SS | 1 |
| Bahceci, E; Hill, JE; Levis, MJ; Perl, AE; Rosales, M; Smith, CC | 1 |
| Chi, S; Harada, S; Izumiyama, K; Kondo, T; Minami, Y; Miyajima, T; Mori, A; Morioka, M; Ogasawara, R; Saito, M; Yokoyama, E | 1 |
| Akashi, K; Egashira, N; Hirota, T; Ieiri, I; Miyamoto, T; Suetsugu, K; Tajima, S; Tsuchiya, Y; Yamauchi, T; Yoshimoto, G; Zhang, M | 1 |
| Eşkazan, AE; Nuhoğlu Kantarcı, E | 1 |
| Chen, CY; Cui, ZL; Fu, Y; Gao, ZX; Liu, F; Ma, S; Zhang, L; Zhou, MR | 1 |
| Guo, MQ; He, YJ; Huang, YX; Li, KX; Li, YH; Pan, WY; Qiu, DZ; Wu, HY; Yang, DH | 1 |
| Lee, T; Mitomi, T; Sugamori, H; Yamagishi, C | 1 |
| Arrigo, G; Audisio, E; Cerrano, M; D'Ardìa, S; Frairia, C; Freilone, R; Giai, V; Secreto, C; Urbino, I | 1 |
| Altman, JK; Chou, WC; Groß-Langenhoff, M; Hasabou, N; Hosono, N; Lee, JH; Levis, MJ; Lu, Q; Martinelli, G; Montesinos, P; Panoskaltsis, N; Perl, AE; Podoltsev, N; Recher, C; Röllig, C; Smith, CC; Strickland, S; Tiu, RV; Yokoyama, H | 1 |
| Aumann, S; Canaani, J; Frisch, A; Ganzel, C; Henig, I; Kugler, E; Moshe, Y; Nachmias, B; Ofran, Y; Raanani, P; Ram, R; Shimony, S; Vainstein, V; Wolach, O; Yeshurun, M | 1 |
| Baker, SD; Bhatnagar, B; Blachly, JS; Blaser, BW; Buelow, DR; Eisenmann, ED; Jeon, JY; Orwick, SJ; Pabla, NS; Stromatt, JC | 1 |
| Altman, JK; Chou, WC; Esteve, J; Gambacorti-Passerini, C; Gill, SC; Havelange, V; Heuser, M; Hill, JE; Laribi, K; Lee, JH; Liu, S; Minden, MD; Montesinos, P; Naoe, T; Patkowska, E; Philipose, N; Rich, ES; Tiu, RV; Wang, ES; Watson, AM; Wu, R | 1 |
| Fu, J; Gu, A; Peng, J; Xu, Y; Yang, B; Zhou, S | 1 |
| Allert, C; Bauer, M; Besenbeck, B; Blank, MF; Bruckmann, M; Göllner, S; Heid, D; Janssen, M; Krijgsveld, J; Müller-Tidow, C; Pauli, C; Renders, S; Rohde, C; Trumpp, A; Waclawiczek, A; Wickenhauser, C; Zimmermann, SMN; Zinz, R | 1 |
| Ciervo, JR; Derkach, A; King, AC; Ranaghan, CP; Stein, ES; Stump, SE; Weis, TM | 1 |
| Aoe, M; Fujiwara, K; Ishida, H; Kanamitsu, K; Nodomi, S; Ochi, M; Tamefusa, K; Tatebe, Y; Washio, K | 1 |
| Adachi, S; Akazawa, R; Hiramatsu, H; Kamitori, T; Kato, I; Saida, S; Takeshita, S; Takita, J; Tasaka, K; Uchihara, Y; Umeda, K; Usami, A; Yoshioka, Y | 1 |
| Asada, N; Ennishi, D; Fujii, K; Fujii, N; Fujiwara, H; Kondo, K; Kondo, T; Maeda, Y; Matsubara, C; Matsumura, A; Matsuoka, KI; Nishimori, H; Terao, T; Ueda, H | 1 |
| Braun, T; Cabannes-Hamy, A; Ghez, D; Goldwirt, L; Jacqz-Aigrain, E; Kelly, L; Kohn, M; Lengline, E; Mourah, S; Puissant, A; Raffoux, E; Rousselot, P; Sauvageon, H; Siavellis, J; Vignal, N | 1 |
| Kim, H; Kim, IS | 1 |
| Fan, G; Gao, J; Liu, G; Luo, P; Qiu, H; Song, X; Wu, J; Yang, Y | 1 |
| Saleh, N | 1 |
| Eskazan, AE; Kucukyurt, S | 1 |
| Perl, AE | 2 |
| Akahane, D; Fujimoto, H; Gotoh, A; Katagiri, S; Moriyama, M; Yoshizawa, S | 1 |
| Baer, MR; Bahceci, E; Berman, E; Chou, WC; Ciceri, F; Cortes, JE; Di Stasi, A; Erba, HP; Fabbiano, F; Fathi, AT; Hasabou, N; Hosono, N; Kasner, M; Larson, RA; Lee, JH; Levis, MJ; Liu, C; Liu, X; Martinelli, G; Montesinos, P; Neubauer, A; Olin, R; Paolini, S; Pardee, T; Perl, AE; Podoltsev, N; Recher, C; Stuart, R; Ustun, C; Yokoyama, H; Yoon, SS | 1 |
| Sidaway, P | 1 |
| DiNardo, CD; Wei, AH | 1 |
| Hussain, MJ; Katz, DA; Larson, M; Miller, I; Nathan, S; Ustun, C; Varma, A; Yun, HD | 1 |
| Alexe, G; Armstrong, SA; Blachly, JS; Byrd, JC; Chu, SH; Cremer, A; Ellegast, JM; Frank, ES; Goodale, A; Häupl, B; Mohr, S; Oellerich, T; Piccioni, F; Pikman, Y; Rao, AV; Robichaud, A; Ross, L; Stegmaier, K; Walker, AR | 1 |
| Rowe, JM | 1 |
| Smith, CC | 1 |
| Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK | 1 |
| Cerella, C; Christov, C; Diederich, M; Ha, YN; Kijjoa, A; Orlikova-Boyer, B; Song, S | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Gokhale, PC; Gray, N; Griffin, JD; Liu, X; Meng, C; Sattler, M; Stone, R; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| Lam, SSY; Leung, AYH | 1 |
| Burnett, A; Stone, R | 1 |
| Aas, IB; Bolstad, B; Dalhus, ML; Enzmann, H; Gisselbrecht, C; Håkonsen, GD; Karpova, N; Lindberg, V; Nilssen, LS; Olsen, HH; Pignatti, F; Rogovska, I; Røshol, H; Tzogani, K; Økvist, M | 1 |
| Chishaki, R; Ito, T; Kida, M; Kido, M; Kuraoka, K; Kuroda, Y | 1 |
| Ando, T; Katsuya, H; Kidoguchi, K; Kimura, S; Kojima, K; Kubota, Y; Kusaba, K; Sano, H; Yamaguchi, K; Yokoo, M; Yoshihara, S | 1 |
| Levis, M; Perl, AE | 1 |
| Elsarrag, RZ; K Keng, M; Pierce, EJ; Reed, DR; Sen, JM | 1 |
| Han, H; Hong, J; Kim, D; Kim, H; Koh, Y; Lee, C; Shin, DY; Yoon, SS | 1 |
| Arakawa, Y; Fukuoka, K; Hiraki, T; Inoue, K; Isobe, K; Koh, K; Mitani, Y; Mori, M; Noguchi, J; Oshima, K; Sugawa, M; Takaki, T; Tomita, O; Tsumura, Y; Yanagi, M | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Naoe, T | 1 |
| Baker, R; Chavda, N; Clark, F; Fielding, AK; Gupta, R; Khwaja, A; Kottaridis, P; Mansour, MR; O'Nions, J; Payne, E; Subhan, M; Thomson, K; Troy-Barnes, E; Wilson, AJ | 1 |
| Dutta, R; Jeng, MY; Mannis, GN; Tan, IT; Zhang, TY | 1 |
| Bever, GJ; Haq, Z; Liu, Y; Pasricha, ND | 1 |
| Xia, X | 1 |
| Bhatnagar, B; Blachly, JS; Blum, WG; Byrd, JC; Crosswell, HE; Lin, TL; Liu, J; Long, L; Mims, AS; Minden, MD; Munugalavadla, V; Oellerich, T; Orwick, S; Pan, Y; Rao, AV; Serve, H; Walker, AR; Zhang, D | 1 |
| Blair, HA; Kang, C | 1 |
| Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
| Abdul-Hamil, NA; Cherchione, C; Martinelli, G; Nagarajan, C; Wong, GC | 1 |
| Ballesta-López, O; Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Solana-Altabella, A | 1 |
| Beaver, L; Blachly, JS; Brinton, LT; Byrd, JC; Canfield, D; Cannon, M; Cempre, C; Govande, M; Harrington, B; Lapalombella, R; Lehman, A; Orwick, S; Sher, S; Skinner, J; Wasmuth, R; Williams, K; Zhang, P | 1 |
| Myers, R; Tollkuci, E; Tran, T | 1 |
| Fleischmann, M; Heidel, FH; Schnetzke, U; Scholl, S | 1 |
| Dobashi, N; Fukushima, R; Gunji, T; Hattori, D; Ishii, H; Ishii, S; Kamitani, I; Katsube, A; Nakano, A; Nishiwaki, K; Oshima, S; Saito, T; Shimada, T; Tanoue, S; Yano, S; Yokoyama, H | 1 |
| Hidaka, K; Mori, M | 1 |
| Fujisawa, S; Harada, S; Izumiyama, K; Kondo, T; Mori, A; Morioka, M; Ogasawara, R; Onozawa, M; Saito, M; Teshima, T | 1 |
| De Claro, RA; Farrell, AT; Fu, W; Goldberg, KB; Gudi, R; Norsworthy, KJ; Okusanya, OO; Pazdur, R; Przepiorka, D; Pulte, ED; Qosa, H; Wang, Y; Xu, Q | 1 |
| Bottomly, D; Druker, BJ; Joshi, SK; McWeeney, SK; Pittsenbarger, J; Sharzehi, S; Tognon, CE; Traer, E | 1 |
| Iwai, F; Kato-Ogura, A; Onaka, T; Otsuka, Y; Yonezawa, A | 1 |
| Bagnato, G; Cerchione, C; Giannini, MB; Marconi, G; Martinelli, G; Mosquera Orgueira, A; Musuraca, G; Simonetti, G | 1 |
| Aleissa, MM; Alshehri, BS; Gonzalez-Bocco, IH; Leblebjian, H; Luskin, MR; Marty, FM; McDonnell, AM | 1 |
| Dzinic, SH; Edwards, H; Ge, Y; Knight, T; Kushner, J; Li, J; Lin, H; Ma, J; Polin, L; Qiao, X; Su, Y; Taub, JW; Wang, G; Wang, J; Wang, L; Wang, Y; White, K | 1 |
| Arshad, OA; Babur, O; Bottomly, D; Cendali, F; D'Alessandro, A; Demir, E; Druker, BJ; Fillmore, TL; Gosline, SJC; Gritsenko, MA; Hansen, JR; Hutchinson, C; Joshi, SK; Kaempf, A; Liu, T; McDermott, JE; McWeeney, SK; Moon, J; Nechiporuk, T; Piehowski, PD; Pittsenbarger, J; Reisz, JA; Rodland, KD; Schepmoes, AA; Shi, T; Tognon, CE; Traer, E; Tsai, CF; Tyner, JW; Wang, YT; Watanabe-Smith, K; Weitz, KK | 1 |
| Abematsu, T; Iijima-Yamashita, Y; Inaba, Y; Kawano, Y; Kodama, Y; Nakagawa, S; Nishikawa, T; Okamoto, Y; Shiba, N; Takahashi, Y | 1 |
| Bidet, A; Desplat, V; Dumas, PY; El-Habhab, A; Fernandez, S; Guitart, AV; Leguay, T; Mansier, O; Martineau, D; Massara, L; Pasquet, JM; Pigneux, A; Vigon, I; Villacreces, A | 1 |
| Baek, JH; Choi, Y; Heo, SK; Jo, JC; Kim, H; Kim, JY; Koh, S; Min, YJ; Noh, EK | 1 |
| Kaneko, N; Kuromitsu, S; Mori, K; Mori, M; Saito, R; Shimada, I; Tanaka, R; Ueno, Y; Yamada, M | 1 |
| Altman, JK; Baer, MR; Bahceci, E; Claxton, D; Cortes, J; Erba, HP; Gill, S; Goldberg, S; Jurcic, JG; Larson, RA; Levis, M; Litzow, M; Liu, C; Martinelli, G; Neubauer, A; Perl, AE; Ritchie, E; Röllig, C; Schiller, G; Smith, C; Spira, AI; Strickland, SA; Stuart, R; Tibes, R; Ustun, C; Wang, ES | 1 |
| Sheridan, C | 1 |
| Baek, JH; Choi, Y; Heo, SK; Jeong, YK; Jo, JC; Kim, H; Kim, JY; Koh, S; Min, YJ; Noh, EK | 1 |
| Baum, A; Beck, J; Engelhardt, H; Gerlach, D; Gerstberger, T; Hofmann, MH; Kaya, O; Kraut, N; Popow, J; Savarese, F; Scharn, D; Schweifer, N; Tontsch-Grunt, U; Zuber, J | 1 |
| Burthem, J; Gorcea, CM; Tholouli, E | 1 |
| Bahceci, E; Iida, H; Kaneko, M; Kobayashi, Y; Kusano, M; Miyamoto, T; Miyawaki, S; Morita, S; Naoe, T; Sakura, T; Takeshita, S; Usuki, K; Yamada, S | 1 |
| Dhillon, S | 1 |
| Tiong, IS; Wei, AH | 1 |
| Li, X; Qi, W; Sun, L; Wang, C; Wang, M; Xu, X; Zhao, D | 1 |
| Cheon, J; Choi, Y; Heo, SK; Jeong, YK; Jo, JC; Ju, LJ; Koh, S; Min, YJ; Noh, EK; Sung, JY; Yu, HM | 1 |
| Canaani, J; Carroll, M; McMahon, CM; Morrissette, JJD; Perl, AE; Qualtieri, JN; Rea, B; Sargent, RL; Watt, CD | 1 |
| Bixby, DL; Marini, BL; Perissinotti, AJ; Weis, TM | 1 |
| Estey, EH; Percival, MM | 1 |
| Dzinic, SH; Edwards, H; Ge, Y; Knight, T; Kushner, J; Lin, H; Ma, J; Polin, L; Qiao, X; Taub, JW; Wang, G; Wang, Y; White, K; Zhao, L; Zhao, S | 1 |
| Bosman, MC; Quax, WJ; Schuringa, JJ; Vellenga, E | 1 |
| Cao, Q; Miller, J; Warlick, ED | 1 |
| Bauvois, B; Billard, C; Bouchet, S; Dauzonne, D; Piedfer, M; Tang, R | 1 |
| Annereau, JP; Bailly, C; Bonnet, D; Brel, V; Créancier, L; Currie, E; Fournier, E; Gomes, B; Guilbaud, N; Guminski, Y; Kruczynski, A; Pillon, A; Vandenberghe, I | 1 |
| Andreeff, M; Carter, BZ; Davis, RE; Ma, W; Mak, DH; Mak, PY; Wang, Z | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; Deangelo, DJ; Fathi, AT; Foster, J; Fraser, JW; McAfee, S; Neuberg, D; Steensma, DP; Stone, RM; Wadleigh, M | 1 |
| Chan, SM; Feng, W; Huang, M; Li, MX; Majeti, R; Mitchell, BS; Thomas, D | 1 |
| Blum, W; Byrd, JC; Devine, SM; Garzon, R; Grever, MR; Humphries, K; Klisovic, RB; Marcucci, G; Schaaf, LJ; Walker, AR | 1 |
| Aplenc, R; Caparas, M; Cullen, P; Johnston, DL; Nagarajan, R; Schulte, F; Sung, L | 1 |
| Anderl, J; Assaraf, YG; Cloos, J; de Haas, V; Degenhardt, J; Franke, NE; Horton, TM; Jansen, G; Kaspers, GJ; Kirk, CJ; Niewerth, D; Schimmer, AD; van Meerloo, J; Zweegman, S | 1 |
| Guzman, ML; Hayslip, J; Howard, DS; Jordan, CT; Liesveld, J; Phillips, GL; Weiss, H | 1 |
| Ahmed, EH; Bernot, KM; Blum, W; Brook, DL; Caligiuri, MA; Dickerson, KE; Dorrance, AM; Garman, S; Lee, RJ; Liu, S; Marcucci, G; Marcucci, GG; McConnell, KK; Mundy-Bosse, BL; Muñoz, MR; Nemer, JS; Santhanam, R; Siebenaler, RF; Whitman, SP; Yang, X; Zhang, J; Zhang, M; Zhang, X; Zorko, NA | 1 |
| de Wijn, R; Eriksson, A; Fryknäs, M; Hilhorst, R; Höglund, M; Hovestad, L; Jarvius, M; Kalushkova, A; Kultima, HG; Larsson, R; Öberg, F; Parrow, V; Rickardson, L | 1 |
| Arai, S; Iwakura, Y; Kagoya, Y; Kataoka, K; Kobayashi, H; Kumano, K; Kurokawa, M; Nakagawa, M; Saito, T; Yoshimi, A | 1 |
| Bloomfield, CD; Carson, WE; de la Chapelle, A; Eisfeld, AK; Hoag, KW; Huang, X; Jarvinen, TM; Leffel, B; Marcucci, G; Markowitz, J; Patel, R; Perrotti, D; Santhanam, R; Schwind, S; Walker, CJ | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N | 1 |
| Adlard, K; Alonzo, TA; Ballard, J; Gamis, AS; Gerbing, RB; Horton, TM; Howard, DS; Jenkins, G; Kelder, A; Moscow, JA; Perentesis, JP; Schuurhuis, GJ; Smith, FO | 1 |
| Chandra, J; Corrales-Medina, FF; Manton, CA; Orlowski, RZ | 1 |
| Baek, JH; Choi, Y; Heo, SK; Jo, JC; Kim, H; Koh, S; Min, YJ; Noh, EK; Park, JH; Yoon, DJ | 1 |
| Thom, C | 1 |
| Stein, EM | 1 |
| Edwards, H; Ge, Y; Li, X; Lin, H; Niu, X; Taub, JW; Wang, G; Wang, Y; Zhao, J | 1 |
| Hernandez, D; Lee, LY; Levis, M; Nguyen, B; Rajkhowa, T; Raman, JR; Small, D; Smith, SC | 1 |
| Benedetti, E; Focosi, D; Galimberti, S; Kast, RE; Metelli, MR; Papineschi, F; Petrini, M | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Adamo, L; Anastasi, G; Caruso, L; Conticello, C; Cupri, A; De Maria, R; Di Raimondo, F; Giuffrida, R; Giustolisi, R; Gulisano, M; Iannolo, G; Moschetti, G; Palumbo, GA; Vicari, L | 1 |
| Chandra, J; Keating, MJ; Miller, CP; Palladino, M; Rudra, S; Wierda, WG | 1 |
| Bousquet-Dubouch, MP; Burlet-Schiltz, O; Gallay, N; Manenti, S; Matondo, M; Monsarrat, B; Payrastre, B; Recher, C; Uttenweiler-Joseph, S | 1 |
| Bruserud, Ø; Ersvaer, E; Hatfield, KJ; Kittang, AO; Lassalle, P; Reikvam, H | 1 |
| Canestraro, M; Cine, N; Galimberti, S; Guerrini, F; Metelli, MR; Nagy, B; Palumbo, GA; Petrini, M; Piaggi, S; Savli, H; Tibullo, D | 1 |
| Badowska, W; Czyzewski, K; Juraszewska, E; Konatkowska, B; Kuzmicz, M; Malinowska, I; Olejnik, I; Pogorzala, M; Sobol, G; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanek, J; Szczepanski, T; Wysocki, M | 1 |
| Bowles, KM; MacEwan, DJ; Rushworth, SA | 1 |
| Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S | 1 |
| Gong, YP; Yang, X; Zheng, BH; Zhou, RQ | 1 |
| Chen, L; Li, JM; Shen, ZX; Wang, AH; Wei, L; Wu, WL; Zhao, SQ | 1 |
| Chen, S; Dai, Y; Dent, P; Grant, S; Kramer, LB; Pei, XY; Wang, L | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Koh, LP; Poon, LM | 1 |
| Fang, Y; He, Q; Jing, H; Luo, P; Song, H; Yang, B; Zhong, L; Zhou, X | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ | 1 |
| Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Curfman, JP; Devine, SM; Eisfeld, AK; Garr, C; Garzon, R; Geyer, S; Grever, MR; Jacob, S; Kefauver, C; Klisovic, R; Marcucci, G; Perrotti, D; Santhanam, R; Schwind, S; Tarighat, SS; Walker, A; Wang, H; Whitman, S | 1 |
| Ades, L; Berger, E; Bordessoule, D; Braun, T; Cahn, JY; Charbonnier, A; Chaury, MP; Cheze, S; Dreyfus, F; Etienne, G; Fenaux, P; Guerci-Bresler, A; Legros, L; Natarajan-Amé, S; Park, S; Ravoet, C; Schmidt, A; Stamatoullas, A; Vey, N | 1 |
| Bolanos, L; Cloos, J; Cortelezzi, A; Cuzzola, M; Fang, J; Goyama, S; Jansen, G; Mulloy, JC; Oliva, EN; Rasch, C; Rhyasen, G; Rigolino, C; Starczynowski, DT; Varney, M; Wunderlich, M | 1 |
| Huang, KK; Jiang, XJ; Meng, FY; Qiao, L; Wang, Q; Wang, ZX; Wu, FQ; Yang, M; Ye, JY; Yi, ZS; Zhao, QX; Zhou, HS | 1 |
| Giralt, S | 1 |
| Amrein, PC; Attar, EC; Bloomfield, CD; Blum, W; DeAngelo, DJ; Johnson, JL; Kolitz, JE; Larson, RA; Lozanski, G; Marcucci, G; Moser, B; Powell, BL; Stone, RM; Voorhees, P; Wadleigh, M; Wang, ES | 1 |
| Bose, P; Grant, S | 1 |
| He, Q; Jing, H; Lin, N; Luo, P; Song, H; Yang, B; Yang, X; Ying, M; Zhong, L; Zhou, X | 1 |
| Binkley, P; Blum, KA; Blum, W; Byrd, JC; Garzon, R; Geyer, S; Grever, MR; Jiang, Y; Johnston, JS; Kefauver, C; Klisovic, R; Marcucci, G; Phelps, MA; Walker, AR | 1 |
| Suzuki, K | 1 |
| Kato, M; Kimura, H; Kobayashi, Y; Kozawa, K; Kuroiwa, M; Minakami, H; Morikawa, A; Oshima, S | 1 |
| Dai, Y; Grant, S; Rahmani, M | 1 |
| Reddy, GK | 1 |
| Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Guerciolini, R; Kantarjian, H; Koller, C; McConkey, D; Patel, G; Ruiz, SL; Thomas, D; Wright, J | 1 |
| Abboud, CN; Bechelli, J; Lancet, JE; Liesveld, JL; Lu, C; Phillips, G; Rosell, KE | 1 |
| Beaupre, DM; Boulware, D; Buzzeo, RW; Colaco, NM; Dalton, WS; Parquet, NA; Perez, LE; Wright, G; Yanamandra, N | 1 |
| Jin, J; Li, Y; Meng, H; Qian, J; Tong, Y | 1 |
| Bruserud, O; Døskeland, AP; Ersvaer, E; Gjertsen, BT; Hatfield, K; Lorens, JB; Ryningen, A; Stapnes, C | 1 |
| Belloc, F; de Verneuil, H; Lacombe, F; Mahon, FX; Milpied, N; Moreau-Gaudry, F; Pigneux, A; Praloran, V; Reiffers, J; Uhalde, M | 1 |
| Baiocchi, RA; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Garzon, R; Huynh, L; Klisovic, RB; Lehmann, E; Liu, S; Liu, Z; Marcucci, G; Pang, J; Perrotti, D; Porcu, P; Takeki, M; Vukosavljevic, T; Wu, LC; Xie, Z; Yu, J | 1 |
| Alvarez-Fernández, S; Colado, E; Garayoa, M; Maiso, P; Martín-Sánchez, J; Montero, JC; Ocio, EM; Pandiella, A; San Miguel, JF; Vidriales, MB | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; D'Amato, F; De Angelo, DJ; Galinsky, I; Levine, J; McAfee, S; Miller, KB; Neuberg, D; Schenkein, D; Sirulnik, A; Stone, RM; Supko, JG; Trehu, EG; Wadleigh, M; Zahrieh, D | 1 |
| Besterman, JM; Cuatrecasas, P | 1 |
| Carlson, J; Cragoe, E; Dorey, F; Koeffler, HP | 1 |
| Kurokawa, H; Nagata, K; Nara, N; Tanikawa, S; Tohda, S; Tomiyama, J | 1 |
| Arima, N; Arimura, K; Fujiwara, H; Hidaka, S; Kukita, T; Matsushita, K; Otsubo, H; Tanaka, H; Yamaguchi, K | 1 |
| Besterman, JM; Cragoe, EJ; Cuatrecasas, P; LeVine, H; May, WS | 1 |
28 review(s) available for pyrazines and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.
Topics: Adult; Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines | 2022 |
Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
Topics: Aged; Aniline Compounds; Azacitidine; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2022 |
New drugs approved for acute myeloid leukaemia in 2018.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Disease-Free Survival; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Progression-Free Survival; Pyrazines; Pyridines; Remission Induction; Sulfonamides | 2019 |
Will new agents impact survival in AML?
Topics: Aniline Compounds; Disease-Free Survival; Drug Approval; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pyrazines; Staurosporine; Survival Rate; United States | 2019 |
The growing landscape of FLT3 inhibition in AML.
Topics: Allografts; Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Middle Aged; Pyrazines; Staurosporine; Stem Cell Transplantation | 2019 |
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2020 |
Overcoming Resistance to FLT3 Inhibitors in the Treatment of
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Drug Therapy, Combination; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2020 |
AML: New Drugs but New Challenges.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrazines | 2020 |
The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
Topics: Adult; Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Mutation; Pyrazines | 2020 |
Gilteritinib: potent targeting of FLT3 mutations in AML.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines | 2020 |
Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines | 2020 |
Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia.
Topics: Aniline Compounds; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyrazines | 2020 |
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine | 2020 |
Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Topics: Aniline Compounds; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Echinocandins; fms-Like Tyrosine Kinase 3; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Mycoses; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Staurosporine; Triazoles | 2020 |
Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2020 |
The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Staurosporine | 2021 |
ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice; Protein Kinase Inhibitors; Pyrazines; Recurrence; Research Design | 2018 |
Gilteritinib: First Global Approval.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Lung Neoplasms; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic | 2019 |
New drugs creating new challenges in acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyridines; Staurosporine; Triazines; United States; United States Food and Drug Administration | 2019 |
Availability of FLT3 inhibitors: how do we use them?
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzothiazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine | 2019 |
Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2019 |
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
Molecularly targeted therapies for acute myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Clinical Trials as Topic; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Phenylurea Compounds; Piperidines; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2015 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
[Current treatment of acute myeloid leukaemia in adults].
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2012 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
26 trial(s) available for pyrazines and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2022 |
Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pyrazines | 2022 |
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Pyrazines | 2022 |
Gilteritinib or Chemotherapy for Relapsed or Refractory
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Mutation; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis | 2019 |
Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies.
Topics: Aged, 80 and over; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclopentanes; Disease-Free Survival; Female; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Pyrazines; Pyridines; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate | 2020 |
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of
Topics: Adult; Cytarabine; Daunorubicin; Female; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Indazoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Ecotropic Viral Integration Site 1 Protein; Pyrazines; Syk Kinase | 2020 |
Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML.
Topics: Aniline Compounds; Azacitidine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines | 2021 |
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Posterior Leukoencephalopathy Syndrome; Pyrazines | 2021 |
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Topics: Aged; Aniline Compounds; Antineoplastic Agents; Blood Platelets; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Phosphorylation; Pyrazines; Recurrence; Retreatment | 2017 |
Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.
Topics: Aged; Aged, 80 and over; Aniline Compounds; Axl Receptor Tyrosine Kinase; Creatine Kinase; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Thrombocytopenia; Treatment Outcome | 2018 |
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide | 2013 |
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2014 |
Reasons for non-completion of health related quality of life evaluations in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Group Processes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Niacinamide; Parents; Phenylurea Compounds; Pyrazines; Quality of Life; Self Report; Sorafenib; Surveys and Questionnaires; Survival Analysis; Young Adult | 2013 |
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Survival Rate | 2013 |
AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia.
Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Dose-Response Relationship, Drug; Down-Regulation; Genes, myc; HL-60 Cells; Humans; Indoles; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Pyrazines; Tumor Cells, Cultured | 2014 |
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Rabbits; Salvage Therapy; Treatment Outcome; Young Adult | 2014 |
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones | 2011 |
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Drug Synergism; Female; Histone Deacetylase 6; Histone Deacetylases; HL-60 Cells; Humans; Hydroxamic Acids; I-kappa B Kinase; Jurkat Cells; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Pyrazines; Signal Transduction; Sulfonamides; Transcription Factor RelA; Tubulin; U937 Cells; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Cell Line, Tumor; Decitabine; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyrazines; Treatment Outcome; Validation Studies as Topic | 2012 |
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyrazines; Survival Analysis; Treatment Outcome | 2012 |
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Topics: Aged; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Follow-Up Studies; Histocompatibility Antigens Class II; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Nervous System; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Electrocardiography; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Male; Middle Aged; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Pyrazines; Recurrence; Torsades de Pointes; Treatment Outcome | 2013 |
New developments with bortezomib in treating multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Division; Doxorubicin; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Liposomes; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Renal Insufficiency; Treatment Outcome | 2004 |
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recurrence; Time Factors | 2004 |
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cohort Studies; Cytarabine; Female; Gene Expression Profiling; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Pyrazines; Tissue Distribution; Treatment Outcome | 2008 |
110 other study(ies) available for pyrazines and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib.
Topics: Aniline Compounds; Bone Marrow; Brain; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome | 2021 |
Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia.
Topics: Aniline Compounds; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines | 2021 |
Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia.
Topics: Aniline Compounds; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-6; Pyrazines; Up-Regulation | 2021 |
Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Salvage Therapy | 2022 |
What to use to treat AML: the role of emerging therapies.
Topics: Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Approval; Drug Discovery; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Triazines | 2021 |
[Successful treatment with gilteritinib for relapsed acute myeloid leukemia with FLT3-N676K mutation].
Topics: Aged; Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines | 2022 |
Development and Validation of an LC-MS/MS Method to Quantify Gilteritinib and Its Clinical Application in Patients With FLT3 Mutation-Positive Acute Myelogenous Leukemia.
Topics: Aniline Compounds; Chromatography, High Pressure Liquid; Chromatography, Liquid; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Limit of Detection; Mutation; Pyrazines; Reproducibility of Results; Tandem Mass Spectrometry | 2022 |
The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cytarabine; Diamines; Leukemia, Myeloid, Acute; Mice; Oxadiazoles; Pyrazines; Reactive Oxygen Species | 2022 |
A novel approach for relapsed/refractory FLT3
Topics: Aniline Compounds; Animals; Disease Models, Animal; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; NF-kappa B p52 Subunit; NK Cell Lectin-Like Receptor Subfamily K; Protein Kinase Inhibitors; Pyrazines; T-Lymphocytes | 2022 |
Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan.
Topics: Aniline Compounds; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Male; Mutation; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Pyrazines | 2022 |
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Retrospective Studies; Sorafenib; Staurosporine | 2022 |
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines | 2022 |
BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein-Tyrosine Kinases; Pyrazines; Tumor Microenvironment | 2022 |
Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines | 2022 |
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.
Topics: Animals; Benzamides; Cell Line, Tumor; Daunorubicin; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Focal Adhesion Kinase 2; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteome; Pyrazines; Sulfonamides | 2022 |
Real-world analysis of the safety/tolerability of gilteritinib in combination with mold-active azole prophylaxis.
Topics: Aniline Compounds; Azoles; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines | 2022 |
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.
Topics: Aniline Compounds; Clinical Trials, Phase III as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Pyrazines | 2022 |
Posttransplant gilteritinib maintenance therapy for pediatric acute myeloid leukemia with myelodysplasia-related changes with FLT3-internal tandem duplication.
Topics: Aniline Compounds; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines | 2023 |
Second relapse of FLT3-ITD-positive acute myeloid leukemia after discontinuation of 3-year post-transplant maintenance therapy with gilteritinib.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2023 |
Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML.
Topics: Aniline Compounds; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Pyrazines | 2023 |
Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Treatment Outcome | 2023 |
Emergence of
Topics: Aniline Compounds; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Pyrazines | 2023 |
Gilteritinib-induced severe immune-related enteritis: a possible case report.
Topics: Aniline Compounds; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines | 2023 |
Gilteritinib Changes AML Landscape.
Topics: Aniline Compounds; Clinical Trials, Phase III as Topic; Drug Approval; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Salvage Therapy; Survival Rate; Treatment Outcome | 2019 |
Improving Response to FLT3 Inhibitors-BCL2 the Rescue?
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine | 2019 |
Successful treatment with gilteritinib for initially FMS-like tyrosine kinase 3 gene internal tandem duplications-positive elderly refractory acute myeloid leukemia that changed into FMS-like tyrosine kinase 3 gene tyrosine kinase domain-positive after co
Topics: Aged; Aniline Compounds; Antineoplastic Agents; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Protein Kinase Inhibitors; Pyrazines | 2019 |
Gilteritinib improves outcomes in AML.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Pyrazines | 2020 |
How I treat acute myeloid leukemia in the era of new drugs.
Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines | 2020 |
Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia.
Topics: Aniline Compounds; Granulocyte Precursor Cells; Humans; Leukemia, Myeloid, Acute; Pyrazines | 2019 |
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphenylamine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Leukemic; Humans; Indazoles; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase Kinases; Mutagenesis, Site-Directed; Mutation; Open Reading Frames; Primary Cell Culture; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyrazines; Syk Kinase; Xenograft Model Antitumor Assays | 2020 |
Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aquatic Organisms; Autophagy; Biological Products; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines; Signal Transduction; U937 Cells; Zebrafish | 2020 |
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine; Syk Kinase | 2020 |
Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Pyrazines; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome | 2020 |
Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
Topics: Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence; Remission Induction; Reoperation; Tandem Repeat Sequences; Tissue Donors; Treatment Outcome | 2020 |
Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia.
Topics: Aniline Compounds; Cell Differentiation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Receptors, Aryl Hydrocarbon | 2020 |
[Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].
Topics: Aniline Compounds; Child; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Pyrazines; Recurrence | 2020 |
Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.
Topics: Adult; Aniline Compounds; COVID-19; COVID-19 Drug Treatment; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Pyrazines; Remission Induction; SARS-CoV-2 | 2020 |
Acute Macular Neuroretinopathy Associated With an Oral FLT3 Inhibitor.
Topics: Administration, Oral; Adult; Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Macula Lutea; Pyrazines; Tomography, Optical Coherence; White Dot Syndromes | 2020 |
Drug efficacy and toxicity prediction: an innovative application of transcriptomic data.
Topics: Aminophenols; Aminopyridines; Animals; Antineoplastic Agents; Benzodioxoles; Cell Death; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Combinations; Drug Development; Epithelial Cells; Gene Expression Profiling; Gene Regulatory Networks; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyrazoles; Quinolones; Toxicity Tests; Transcriptome | 2020 |
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
Topics: Aniline Compounds; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Pyrazines; Recurrence; Retreatment; Treatment Outcome | 2021 |
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; CRISPR-Cas Systems; Female; fms-Like Tyrosine Kinase 3; Gene Knockout Techniques; Genetic Therapy; Humans; Leukemia, Myeloid, Acute; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine; Sulfonamides | 2020 |
Gilteritinib administration in a hemodialysis patient.
Topics: Aged; Aniline Compounds; Female; Humans; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Recurrence; Renal Dialysis | 2021 |
Successful bridge therapy of gilteritinib to cord blood transplantation in relapsed acute myeloid leukemia after bone marrow transplantation.
Topics: Adult; Aniline Compounds; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Pyrazines | 2021 |
[Pharmacological and clinical profile of gilteritinib (Xospata
Topics: Adult; Aniline Compounds; Animals; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Mice; Mutation; Pyrazines; Tablets; United States | 2021 |
Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of
Topics: Adolescent; Aniline Compounds; Biopsy; Blast Crisis; Bone Marrow; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Male; Monocytes; Protein Kinase Inhibitors; Pyrazines; Radiography, Thoracic; Tandem Repeat Sequences | 2021 |
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
Topics: Aniline Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Models, Molecular; Mutation; Protein Kinase Inhibitors; Pyrazines | 2021 |
A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer.
Topics: Aniline Compounds; Bone Marrow Neoplasms; fms-Like Tyrosine Kinase 3; Gonadotropin-Releasing Hormone; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Oligopeptides; Prostatic Neoplasms; Pyrazines | 2022 |
Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antifungal Agents; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Prognosis; Pyrazines; Retrospective Studies; Survival Rate; Triazoles; Young Adult | 2021 |
The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, Transgenic; Morpholines; Pyrazines; Pyrimidines; THP-1 Cells; Xenograft Model Antitumor Assays | 2021 |
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.
Topics: Aniline Compounds; Aurora Kinase B; Biomarkers, Tumor; Drug Resistance, Neoplasm; Exome; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Metabolome; Protein Kinase Inhibitors; Proteome; Pyrazines; Tumor Cells, Cultured; Tumor Microenvironment | 2021 |
Pediatric acute myeloid leukemia co-expressing FLT3/ITD and NUP98/NSD1 treated with gilteritinib plus allogenic peripheral blood stem cell transplantation: A case report.
Topics: Aniline Compounds; Child; fms-Like Tyrosine Kinase 3; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Pore Complex Proteins; Peripheral Blood Stem Cell Transplantation; Pyrazines | 2021 |
Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in
Topics: Aniline Compounds; Axl Receptor Tyrosine Kinase; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases | 2021 |
Radotinib induces high cytotoxicity in c-KIT positive acute myeloid leukemia cells.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Cell Line, Tumor; Female; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Proto-Oncogene Proteins c-kit; Pyrazines | 2017 |
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Disease Models, Animal; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2017 |
First new drug approval for AML in 15 years.
Topics: Aminoglycosides; Aminopyridines; Aniline Compounds; Antibodies, Monoclonal, Humanized; Drug Approval; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Staurosporine; Triazines | 2017 |
Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.
Topics: Animals; Apoptosis; Apoptotic Protease-Activating Factor 1; Benzamides; Cell Line, Tumor; Dasatinib; Drug Delivery Systems; Female; Gene Expression Regulation, Leukemic; HSP90 Heat-Shock Proteins; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Nude; Proto-Oncogene Proteins c-kit; Pyrazines; Xenograft Model Antitumor Assays | 2017 |
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 9; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Enhancer Elements, Genetic; Flavonoids; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Piperidines; Proteins; Pyrazines; RNA Polymerase II; RNA-Binding Proteins; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Closing in on targeted therapy for acute myeloid leukaemia.
Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2019 |
Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA Damage; Dose-Response Relationship, Drug; Humans; Isoxazoles; Leukemia, Myeloid, Acute; Protein-Tyrosine Kinases; Pyrazines; U937 Cells | 2019 |
Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression.
Topics: Animals; Apoptosis; Aurora Kinase A; Benzamides; Cell Cycle; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Nude; Mitosis; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Gilteritinib induces differentiation in relapsed and refractory
Topics: Aniline Compounds; Cell Differentiation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines; Recurrence | 2019 |
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Topics: Aniline Compounds; Animals; Apoptosis; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine; Sulfonamides; Xenograft Model Antitumor Assays | 2019 |
Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
Topics: Antigens, CD34; Boronic Acids; Bortezomib; Coculture Techniques; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; I-kappa B Kinase; Imidazoles; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplastic Stem Cells; NF-kappa B; Primary Cell Culture; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quinoxalines; Recombinant Proteins; RNA, Small Interfering; Stromal Cells; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2013 |
Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazines; Treatment Outcome; Vorinostat | 2013 |
p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Cell Proliferation; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Flavonoids; Flow Cytometry; Humans; Immunoenzyme Techniques; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Middle Aged; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Ribosomal Protein S6 Kinases, 70-kDa; Tumor Cells, Cultured | 2013 |
F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cytarabine; Deoxycytidine; Doxorubicin; Fetal Blood; Flow Cytometry; Gemcitabine; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Podophyllotoxin; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Survival; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation, Leukemic; HL-60 Cells; HSP72 Heat-Shock Proteins; Humans; I-kappa B Proteins; Leukemia, Myeloid, Acute; Leupeptins; Myeloid Cell Leukemia Sequence 1 Protein; NF-KappaB Inhibitor alpha; Oligonucleotides, Antisense; Oligopeptides; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Nucleolus; Cell Proliferation; Cysteine; Cytosol; Drug Resistance, Neoplasm; Flow Cytometry; Free Radical Scavengers; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Nucleophosmin; Oxides; Pyrazines; Reactive Oxygen Species; Tryptophan; Tumor Cells, Cultured | 2013 |
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
Topics: Adolescent; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines | 2013 |
Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA Methylation; Drug Carriers; fms-Like Tyrosine Kinase 3; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Experimental; Leukemia, Myeloid, Acute; Liposomes; Mice; Mice, Mutant Strains; MicroRNAs; Mutation; Myeloid-Lymphoid Leukemia Protein; Proteasome Inhibitors; Pyrazines; RNA, Neoplasm; Tandem Repeat Sequences | 2013 |
Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.
Topics: Active Transport, Cell Nucleus; Adult; Aged; Animals; Bone Marrow Cells; Boronic Acids; Bortezomib; Disease Progression; Female; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Fluorescence; Middle Aged; NF-kappa B; Phenotype; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha | 2014 |
Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosomes; Computational Biology; Core Binding Factor Alpha 2 Subunit; Cytogenetics; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Introns; Leukemia, Myeloid, Acute; Male; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplasm Proteins; NF-kappa B; Phenotype; Pyrazines; RNA, Messenger; Tumor Suppressor Protein p53 | 2014 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyrazines; Retrospective Studies; Thalidomide; Time Factors | 2014 |
Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Hydroxamic Acids; Indoles; Lactones; Leukemia, Myeloid, Acute; Panobinostat; Proteasome Inhibitors; Pyrazines; Pyrroles; Tumor Cells, Cultured | 2015 |
Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia Cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Benzamides; CD11b Antigen; Cell Line, Tumor; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; src-Family Kinases; Tretinoin | 2015 |
Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients.
Topics: Aniline Compounds; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2015 |
Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; G2 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mitosis; Myeloid Cell Leukemia Sequence 1 Protein; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; THP-1 Cells; U937 Cells | 2016 |
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
Topics: Aniline Compounds; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Pyrazines | 2017 |
Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure.
Topics: Cell Division; Chemokine CXCL12; Dipeptidyl-Peptidase IV Inhibitors; Female; Graft Rejection; Hematopoietic Stem Cells; Humans; Hydrolysis; Leukemia, Myeloid, Acute; Middle Aged; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Triazoles | 2009 |
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle Proteins; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand | 2008 |
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Topics: Acetylation; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Drug Synergism; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Immunoprecipitation; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Oxidative Stress; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Superoxides; Tumor Cells, Cultured; Vorinostat | 2009 |
Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Daunorubicin; Drug Resistance, Neoplasm; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leupeptins; Male; Middle Aged; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured; U937 Cells | 2010 |
Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-1; Angiopoietin-2; Antibodies; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Coculture Techniques; Endothelial Cells; Female; Fibroblasts; Hepatocyte Growth Factor; Humans; Imidazoles; Interleukin-8; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Osteoblasts; Proteoglycans; Pyrazines; Quinoxalines; Receptor Cross-Talk; Receptor, TIE-2; Signal Transduction | 2010 |
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blast Crisis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 8; Cell Cycle; Cell Proliferation; Drug Synergism; Gene Expression Profiling; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; NF-kappa B; Oligonucleotide Array Sequence Analysis; Oxides; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2010 |
Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia.
Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines | 2010 |
High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Basic-Leucine Zipper Transcription Factors; Blotting, Western; Boronic Acids; Bortezomib; Cell Nucleus; Cell Separation; Chromatin Immunoprecipitation; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group Proteins; Flow Cytometry; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2; Proteasome Endopeptidase Complex; Pyrazines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
[Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Daunorubicin; Drug Synergism; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Tumor Cells, Cultured; Young Adult | 2010 |
Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazines; Signal Transduction; Valproic Acid | 2011 |
Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib.
Topics: ABO Blood-Group System; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Pyrazines; Red-Cell Aplasia, Pure; Transplantation, Homologous | 2012 |
Involvement of mitogen-activated protein kinase in signal transducer and activator of transcription-1 mediated differentiation induced by bortezomib in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Enzyme Inhibitors; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Phosphorylation; Pyrazines; STAT1 Transcription Factor; Tumor Cells, Cultured | 2013 |
Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.
Topics: Antineoplastic Agents; Autophagy; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials, Phase II as Topic; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Lysosomes; Multicenter Studies as Topic; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; TNF Receptor-Associated Factor 6 | 2012 |
Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways.
Topics: Acetylation; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; NF-kappa B; Panobinostat; Poly(ADP-ribose) Polymerases; Proteolysis; Proto-Oncogene Proteins c-akt; Pyrazines | 2012 |
Graft-versus-host disease: have we solved the problem?
Topics: Antigens, CD34; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Pyrazines; Siblings; T-Lymphocyte Subsets | 2012 |
Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Checkpoint Kinase 1; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Pyrazines | 2012 |
Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Pyrazines; Random Allocation; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; STAT1 Transcription Factor; Tretinoin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Superoxide radical generation and Mn- and Cu-Zn superoxide dismutases activities in human leukemic cells.
Topics: Adult; Anions; Child; Humans; Imidazoles; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukocytes; Manganese; Monocytes; N-Formylmethionine Leucyl-Phenylalanine; Oxidative Stress; Oxygen; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Sodium Dodecyl Sulfate; Superoxide Dismutase; Superoxides; Tetradecanoylphorbol Acetate; Zymosan | 2003 |
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Topics: Anisomycin; Antineoplastic Agents; Apoptosis; Blast Crisis; Boronic Acids; Bortezomib; Cyclin-Dependent Kinases; Cysteine Endopeptidases; Enzyme Inhibitors; Flavonoids; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia, Myeloid, Acute; Leupeptins; Mitogen-Activated Protein Kinases; Multienzyme Complexes; NF-kappa B; Piperidines; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; U937 Cells | 2003 |
Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Communication; Cell Survival; Coculture Techniques; Cytarabine; Endothelial Cells; Humans; Leukemia, Myeloid, Acute; Proteasome Inhibitors; Pyrazines | 2005 |
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fibronectins; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Pyrazines; Quinolones; Stromal Cells; Tumor Cells, Cultured | 2006 |
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chickenpox; Dexamethasone; Disease Susceptibility; Doxorubicin; Female; Herpesvirus 3, Human; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Virus Activation | 2007 |
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Oligopeptides; Protease Inhibitors; Pyrazines | 2007 |
Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leupeptins; Male; Membrane Proteins; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyrazines; Tumor Cells, Cultured | 2007 |
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Silencing; Humans; Leukemia, Myeloid, Acute; NF-kappa B; Protein Kinases; Pyrazines; Transcription, Genetic | 2008 |
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Topics: Aged; Antigens, CD34; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Middle Aged; Phenotype; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2008 |
Phorbol esters rapidly stimulate amiloride-sensitive Na+/H+ exchange in a human leukemic cell line.
Topics: Amiloride; Carrier Proteins; Cell Line; Humans; Kinetics; Leukemia, Myeloid, Acute; Phorbol 12,13-Dibutyrate; Phorbol Esters; Phorbols; Pyrazines; Sodium-Hydrogen Exchangers; Tetradecanoylphorbol Acetate | 1984 |
Amiloride potentiation of differentiation of human promyelocytic cell line HL-60.
Topics: Amiloride; Cell Line; Dimethyl Sulfoxide; Drug Synergism; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Pyrazines; Structure-Activity Relationship | 1984 |
Effect of vesnarinone, a quinolinone derivative, on the growth of leukemic blasts in acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cell Division; Colony-Forming Units Assay; Female; Hematopoiesis; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyrazines; Quinolines; Tumor Cells, Cultured | 1997 |
Vesnarinone exhibits antitumor effect against myeloid leukemia cells via apoptosis.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Cell Division; DNA Fragmentation; Dose-Response Relationship, Drug; fas Receptor; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quinolines; Tumor Cells, Cultured | 1997 |
Amiloride inhibits phorbol ester-stimulated Na+/H+ exchange and protein kinase C. An amiloride analog selectively inhibits Na+/H+ exchange.
Topics: Amiloride; Carrier Proteins; Cell Adhesion; Cell Differentiation; Cell Line; Humans; Leukemia, Myeloid, Acute; Phorbol 12,13-Dibutyrate; Phorbol Esters; Phorbols; Phosphorylation; Protein Kinase C; Protein Kinase Inhibitors; Pyrazines; Receptors, Cell Surface; Receptors, Transferrin; Sodium-Hydrogen Exchangers | 1985 |